By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


NovaBay Pharmaceuticals, Inc. 

5980 Horton Street
Suite 550
Emeryville  California  94608  U.S.A.
Phone: 510-899-8800 Fax: 510-779-5468

NovaBay Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with its two distinct categories of products: Aganocide® compounds and NeutroPhase®. Aganocide compounds, led by NVC-422, are patented, synthetic molecules with a broad spectrum of activity against bacteria, viruses and fungi. Mimicking the mechanism of action that human white blood cells use against infections, Aganocides possess a very low likelihood that bacteria or viruses will be able to develop resistance, which is critical for advanced anti-infectives. Having demonstrated clinical efficacy in Phase 2 proof-of-concept clinical studies, NVC-422 is suited to treat and prevent a wide range of local, non-systemic infections. NovaBay’s clinical development activities are focused on three disease areas: Dermatology, Ophthalmology and Urology.

NovaBay has entered into a licensing and research collaboration agreement with Galderma S.A., a global leading pharmaceutical company dedicated exclusively to the field of dermatology. NovaBay is also developing NeutroPhase, which is an FDA 510(k)-cleared product for advanced wound care. NovaBay believes that NeutroPhase is the only patented pure hypochlorous acid solution available which has the potential to be best suited to treat the six-million-patients in the U.S. who suffer from chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers.

Key Statistics

Ownership: Public

Web Site: NovaBay
Symbol: NBY

Company News
NovaBay (NBY) Expects Fourth Quarter 2015 Avenova Sales To Exceed $1.5 Million 1/11/2016 12:40:41 PM
NovaBay (NBY) Secures $3 Million Bridge Loan 1/7/2016 12:19:54 PM
NovaBay (NBY) Declares Reverse Stock Split 12/14/2015 12:57:54 PM
NovaBay (NBY) CEO Steps Down Amid Corporate Restructuring 11/19/2015 6:19:05 AM
NovaBay (NBY) Reschedules Third Quarter 2015 Conference Call To November 19 11/16/2015 11:15:36 AM
NovaBay (NBY) Reschedules Third Quarter 2015 Conference Call To November 16 11/11/2015 10:46:52 AM
NovaBay (NBY) To Hold Third Quarter 2015 Conference Call On November 13 11/5/2015 1:19:56 PM
NovaBay (NBY) Completes 34 Patient Phase 2B Clinical Study 11/4/2015 9:04:22 AM
NovaBay (NBY) Announces Pricing Of Public Offering Of Common Stock And Warrants 10/23/2015 10:05:13 AM
NovaBay (NBY) Provides Update On Avenova Sales Growth, Reports Progress With intelli-Case Test Market Launch And Product Pipeline Advancement 10/8/2015 11:26:18 AM